Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-04-03 00:00:00 ET · period of report 2025-04-01 · accession 0000950170-25-050584 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-04-03 | 2025-04-01 | BBIO | Ellis Andrea | Dir | S - Sale+OE | $34.05 | -30.0K | 12.0K | -71% | -$1.02M |
| DT | 2025-04-03 | 2025-04-01 | BBIO | Ellis Andrea | Dir | M - OptEx | $8.45 | +30.0K | 42.0K | +250% | +$253.5K |
| DT | 2025-04-03 | 2025-04-01 | BBIO | Ellis Andrea | Dir | M - OptEx | $0.00 | -30.0K | 74.9K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-01 | S | D | 30,000 | $34.05 | 12,000 | D | — | — | |
| 2 | Common | Common Stock | 2025-04-01 | M | A | 30,000 | $8.45 | 42,000 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2025-04-01 | M | D | 30,000 | $0.00 | 74,921 | D | $8.45 · — to 2032-06-22 | 30,000 Common Stock | (F2) The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors. |